S-腺苷甲硫氨酸（SAM-e）用于治疗感染艾滋病毒/艾滋病患者的抑郁症。
S-adenosylmethionine (SAM-e) for the treatment of depression in people living with HIV/AIDS.
作者信息
Shippy R Andrew, Mendez Douglas, Jones Kristina, Cergnul Irene, Karpiak Stephen E
机构信息
ACRIA (AIDS Community Research Initiative of America), 230 West 38th St, 17th Floor, New York, NY 10018, USA.
出版信息
BMC Psychiatry. 2004 Nov 11;4:38. doi: 10.1186/1471-244X-4-38.
BACKGROUND
This study reports on clinical data from an 8-week open-label study of 20 HIV-seropositive individuals, diagnosed with Major Depressive Disorder (DSM-IV), who were treated with SAM-e (S-Adenosylmethionine). SAM-e may be a treatment alternative for the management of depression in a population reluctant to add another "pill" or another set of related side effects to an already complex highly active antiretroviral therapy (HAART) regimen.
METHODS
The Hamilton Rating Scale for Depression (HAM-D) and the Beck Depression Inventory (BDI) were used to assess depressive symptomatology from 1,2,4,6 and 8 weeks after initiation of treatment with SAM-e.
RESULTS
Data show a significant acute reduction in depressive symptomatology, as measured by both the HAM-D and the BDI instruments.
CONCLUSIONS
SAM-e has a rapid effect evident as soon as week 1 (p < .001), with progressive decreases in depression symptom rating scores throughout the 8 week study.
背景
本研究报告了一项针对20名被诊断患有重度抑郁症（DSM-IV）的HIV血清反应阳性个体进行的为期8周的开放标签研究的临床数据，这些个体接受了S-腺苷甲硫氨酸（SAM-e）治疗。对于那些不愿意在已经复杂的高效抗逆转录病毒疗法（HAART）方案中再增加一种“药物”或另一组相关副作用的人群，SAM-e可能是一种治疗抑郁症的替代方法。
方法
使用汉密尔顿抑郁量表（HAM-D）和贝克抑郁量表（BDI）在开始使用SAM-e治疗后的第1、2、4、6和8周评估抑郁症状。
结果
数据显示，通过HAM-D和BDI工具测量，抑郁症状有显著的急性减轻。
结论
SAM-e在第1周就有明显的快速效果（p < .001），在整个8周的研究中抑郁症状评分分数逐渐下降。
Zotero 插件